Characteristics of taste alterations in people receiving taxane-based chemotherapy and their association with appetite, weight, and quality of life

ConclusionsAlmost 60% of patients receiving taxane-based regimens, especially docetaxel, reported taste alterations. Taste alteration affected the patient ’s appetite but did not affect the weight or QOL. Docetaxel therapy, previous chemotherapy, dry mouth, and peripheral neuropathy were independent risk factors for taste alterations.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research